adminEli Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea
32 minutes ago
Eli Lilly’s (LLY) Zepbound has received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea for adults with obesity, the drugmaker announced late Friday.
The approval comes after several trials earlier this year that showed the tirzepatide-based drug is five times more effective than a placebo at reducing breathing disruptions caused by obstructive sleep apnea (OSA) and in 50% of cases, completely preventing them.
"Nearly half of clinical trial patients saw such improvements that they no longer had symptoms associated with OSA, marking a critical step forward in reducing the burden of this disease and its interconnected health challenges," Jonsson said.
Zepbound got FDA approval to treat obesity and weight loss in November 2023, joining Eli Lilly’s other tirzepatide-based drug, Mounjaro. The two drugs, along with Novo Nordisk’s (NVO) Ozempic and Wegovy, have captured the majority of a surging weight-loss market that has grown substantially in recent years.
Eli Lilly shares were up more than 2% in midday trading Monday, having gained about 34% on the year. Shares of ResMed (RMD), a medical device company that makes much of its revenue through the sale of sleep apnea masks, were 4% lower on Monday and have been negatively affected previously by the sleep apnea trials for Zepbound.
-Aaron McDade
Rumble Stock Soars After Video Platform Gets $775M Investment From Tether
1 hr 29 min ago
Rumble (RUM) shares skyrocketed Monday morning after the video platform received a $775 million investment from Tether, operator of a cryptocurrency platform and creator of the stablecoin of the same name.
Rumble announced that Tether had purchased 103.3 million shares of Rumble for $7.50 each. It noted that the transaction would not change the status of Chief Executive Officer (CEO) Chris Pavlovski as the firm’s majority stakeholder. The transaction is expected to close in the first quarter of 2025.
The company said it will use $250 million of the proceeds to “support growth initiatives and the remaining proceeds to fund a self tender offer for up to 70 million of its Class A Common Stock, at the same price.”
Oppenheimer wrote in a note to clients that for Rumble, the deal “should alleviate investor concerns related to liquidity” ahead of positive free cash flow. It has a “perform” rating on the stock.
Shares of Rumble were up 80% Monday morning at $13.20, their highest level since November 2022.
-Bill McColl
Honda Stock Surges as Automaker Plans To Merge With Nissan in 2026
2 hr 34 min ago
Honda’s (HMC) U.S.-listed shares popped Monday morning after the Japanese automaker and Nissan announced the signing of a memorandum of understanding (MOU) outlining their plans to merge in 2026.
The automakers plan to finalize the terms over the next several months and announce a definitive agreement in June 2025. A combined entity is expected to be listed on the Tokyo Stock Exchange in August 2026, the companies said.
Honda also announced a plan to buy back up to 1.1 trillion Japanese yen ($7 billion) worth of the automaker’s own stock over the next calendar year, replacing a 100 billion yen ($636.3 million) plan announced last month.
Japanese regulators have not explicitly spoken about the Honda-Nissan deal, but Yoji Muto, head of the Ministry of Economy, Trade and Industry, said last Friday that the government "should take a favorable view when companies cooperate to strengthen their competitiveness," The Wall Street Journal reported.
Honda's U.S.-listed shares soared 13% in early trading Monday after entering the day down about 23% this year.
-Aaron McDade
Stock Futures Mixed To Start Holiday-Shortened Week
3 hr 29 min ago
Futures contracts connected to the Dow Jones Industrial Average traded 0.5% lower in premarket trading on Monday.
S&P 500 futures were off 0.2%.
Nasdaq 100 futures were barely hanging onto gains shortly before markets opened.
Article Sources Investopedia requires writers to use primary sources to support their work. These include white papers, government data, original reporting, and interviews with industry experts. We also reference original research from other reputable publishers where appropriate. You can learn more about the standards we follow in producing accurate, unbiased content in our editorial policy.
-
Eli Lilly. "FDA Approves Zepbound® (Tirzepatide) as the First and Only Prescription Medicine for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity."
-
Rumble. "Rumble Announces $775 Million Strategic Investment from Tether."
-
Honda. "Nissan and Honda sign MOU to consider business integration."
-
Honda. "Notice Concerning Status and Suspension of Acquisition of the Company’s Own Shares and Determination of Matters Related to the Acquisition of Own Shares."
-
The Wall Street Journal. "Honda, Nissan Plan to Create World’s No. 3 Automaker in 2026 Merger."
Take the Next Step to Invest Advertiser Disclosure × The offers that appear in this table are from partnerships from which Investopedia receives compensation. This compensation may impact how and where listings appear. Investopedia does not include all offers available in the marketplace.
